Results of NRG-RTOG 0436 highlight need for biomarkers in treatment of esophageal cancer

(NRG Oncology) NRG-RTOG 0436 has determined that adding an epidermal growth factor receptor (EGFR) inhibitor to a chemo-radiation regimen does not improve overall survival for patients with locally advanced esophageal cancer treated in a non-operative manner. These results are reported in 'Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients with Esophageal Cancer -- The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial,' which was recently published in the Journal of the American Medical Association Oncology.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news